NCT00269035View on ClinicalTrials.gov

SPECT Study With SB-773812 In Schizophrenic Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

June 21, 2005

Primary Completion Date

May 26, 2007

Study Completion Date

May 26, 2007

Conditions
Schizophrenia
Interventions
DRUG

SB773812

SB-773812 tablets will be available with dose strength of 60 mg

DRUG

Risperidone

Risperidone tablets will be available with dose strength of 3 and 6 mg

Trial Locations (6)

08003

GSK Investigational Site, Barcelona

08025

GSK Investigational Site, Barcelona

08035

GSK Investigational Site, Barcelona

Unknown

GSK Investigational Site, Mataro (Barcelona)

08830

GSK Investigational Site, Sant Boi de Llobregat

08500

GSK Investigational Site, Vic (Barcelona)

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00269035 - SPECT Study With SB-773812 In Schizophrenic Patients | Biotech Hunter | Biotech Hunter